Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Immune Checkpoint Remmer (ICR)-Geneesmiddel-Geneesmiddel Interactie (GGI)-studie

16 november 2026 bijgewerkt door: Tyler Andrew Shugg, Indiana University

Beoordeling van geneesmiddelinteracties tussen immuuncheckpointremmers en cytochroom P450 substraten: Immuuncheckpointremmer (ICI)-geneesmiddelinteractie (DDI) studie

Immune checkpoint inhibitors (ICIs) (also called "immunotherapy") are an effective family of anti-cancer drugs, but they can cause serious side effects. Some evidence suggests these side effects might happen because ICIs interact with other drugs that you may already be taking, making those drugs work differently, or causing more side effects. The purpose of this study is to see whether ICIs impact how the liver processes other drugs. To do this, participants will be given a probe cocktail of 7 different FDA-approved drugs that are processed in different ways in the liver.

Studie Overzicht

Toestand

Nog niet aan het werven

Interventie / Behandeling

Gedetailleerde beschrijving

Findings suggest that adverse events during checkpoint inhibitor therapy may, in part, be caused by drug-drug interactions that increase the risk of adverse events with co-administered medications. Identifying these novel drug-drug interactions will likely inform clinical strategies to reduce adverse events during checkpoint inhibitor therapy and enhance their clinical benefits.

This current research aims to systematically explore the impact of ICIs on CYP/transporter function and the associated risks for adverse events, thereby informing clinical strategies to mitigate these risks and optimize the therapeutic benefits of checkpoint inhibitors. By employing a rigorous crossover drug-drug interaction design, this study seeks to enhance understanding of drug interactions during ICI therapy, ultimately improving patient outcomes in oncology.

The long-term goal of this research is to find ways to manage adverse events that occur during treatment with ICIs. The research has two main aims:

  1. To understand how ICI therapy affects the metabolism of certain drugs named CYP/transporter probe drugs and to also understand the risk of side effects from commonly prescribed drugs that are affected by these enzymes and transporters in cancer patients.
  2. To examine the relationship between levels of pro-inflammatory cytokines (signaling molecules involved in inflammation) and how well these probe drugs are metabolized before and during ICI therapy.

A two-phase clinical study will be conducted to achieve these aims: patients will be given seven different probe drugs that interact with key enzymes and transporters (CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A, BCRP, and SLCO1B1) both before they start ICI treatment and after they have begun therapy.

Adverse events will be assessed by looking at how changes in the function of these enzymes and transporters affect the metabolism of drugs that cancer patients commonly use. Special computer models, known as physiologically-based pharmacokinetic (PBPK) models, will be used to simulate how these drugs behave in the body and predict potential serious adverse events.

Studietype

Ingrijpend

Inschrijving (Geschat)

80

Fase

  • Vroege fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Indiana
      • Indianapolis, Indiana, Verenigde Staten, 46202
        • Indiana University Melvin and Bren Simon Comprehensive Cancer Center
        • Contact:
        • Hoofdonderzoeker:
          • Tyler Shugg, MD

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • ≥ 18 years old at the time of informed consent
  • Diagnosed with cancer AND initiating therapy with single agent or combination therapy that includes an immune checkpoint inhibitor (e.g., atezolizumab, cemiplimab, durvalumab, ipilimumab, nivolumab, pembrolizumab, relatlimab, tremelimumab)
  • Ability to provide written informed consent and HIPAA authorization

Exclusion Criteria:

  • Actively pregnant or breastfeeding

  • Body weight less than 50 kg or a BMI >35

  • Low baseline hemoglobin, defined as <10 g/dL

    • Note: if a prospective patient's hemoglobin returns to the normal range, they can be re-screened for trial inclusion)
  • Past medical history of chronic liver disease, signs and symptom of liver disease (e.g., jaundice, ascites), or aspartate aminotransferase >96 U/L, alanine aminotransferase > 80 IU/L, alkaline phosphatase >260 U/L, or total bilirubin > 2.6 mg/dL

    • Note: if a prospective patient's liver function tests return to the normal ranges, they can be re-screened for trial inclusion)
  • Past medical history of chronic kidney disease, signs and symptom of kidney disease (e.g., decreased urine output, swelling in feet and ankles), or estimated glomerular filtration rate <45 mL/minute/1.73 m2 BSA

    • Note: if a prospective patient's kidney function returns to the normal range, they can be re-screened for trial inclusion)
  • Poor performance status that makes it unlikely the patient will complete 3 cycles of immune checkpoint inhibitor (at the treating oncologist's discretion)

  • Diagnosis or past medical history of autoimmune disorder, including systemic lupus erythematosus, Crohn's disease, Sjogren's syndrome, multiple sclerosis, type 1 diabetes mellitus, Behcet's disease, and ankylosing spondylitis

  • History of intolerance, allergic reaction, or hypersensitivity to any of the study drugs (tizanidine, bupropion, flurbiprofen, omeprazole, dextromethorphan, midazolam, rosuvastatin)

  • Current infection requiring medical treatment (note: if a prospective patient's infection resolves, they can be re-screened for trial inclusion)

  • Concomitant treatment with systemic immunosuppressant drugs (see Appendix 3 for list)

    • Note: patients may be re-screened for trial eligibility if they discontinue any exclusionary drugs for ≥7 days prior to Study Visit 1
  • Concomitant treatment with a CYP/transporter probe cocktail drug or strong inhibitors, inducers, or agents that affect the pharmacokinetics of the relevant CYP enzymes or drug transporters (see Appendix 4 for list)

    • Note: patients may be re-screened for trial eligibility if they discontinue any exclusionary drugs for ≥7 days prior to Study Visit 1
  • Are unwilling/unable to avoid drugs of abuse, tobacco products or marijuana, or consuming more than 2 alcoholic drinks per day during the study

  • Inability to take oral medication

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Fundamentele wetenschap
  • Toewijzing: Niet-gerandomiseerd
  • Interventioneel model: Crossover-opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Cohort 1

CYP enzyme/drug transporter probe substrates administered at two study visits: one before initiation of ICI therapy and one while on therapy.

Low dose of a cocktail of probe substrates for eight major CYP enzymes/drug transporters.

Experimenteel: Cohort 2

CYP enzyme/drug transporter probe substrates administered at one study visit: during ICI therapy.

Low dose of a cocktail of probe substrates for eight major CYP enzymes/drug transporters.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Tijdsspanne
Verandering in plasmaconcentraties door geneesmiddelblootstelling tijdens ICI-therapie
Tijdsspanne: baseline (voor aanvang van ICI-therapie) tot en met dag 84
baseline (voor aanvang van ICI-therapie) tot en met dag 84
Toxiciteitsconcentraties voor CYP/transporter-substraatgeneesmiddelen in plasma
Tijdsspanne: baseline (dag voor start Cyclus 1) tot dag 84
baseline (dag voor start Cyclus 1) tot dag 84
Associaties tussen concentraties van pro-inflammatoire cytokines en concentraties van CYP/transporter probes in plasma
Tijdsspanne: baseline (dag voor start Cyclus 1) tot dag 84
baseline (dag voor start Cyclus 1) tot dag 84

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Assess associations between T cells populations and CYP/transporter probe drug concentrations
Tijdsspanne: baseline (day before Cycle 1 start) up to day 84

Peripheral blood mononuclear cells (PBMCs)

baseline (day before Cycle 1 start) up to day 84
Concentrations of endogenous biomarkers
Tijdsspanne: baseline (day before Cycle 1 start) up to day 84

Plasma or urine

baseline (day before Cycle 1 start) up to day 84
CYP/transporter endogenous biomarker concentrations
Tijdsspanne: baseline (day before Cycle 1 start) up to day 84

Plasma or urine correlated with plasma concentrations of pro-inflammatory cytokines

baseline (day before Cycle 1 start) up to day 84
Correlation of concentration of population of activated T cells and CYP/transporter endogenous biomarkers
Tijdsspanne: baseline (day before Cycle 1 start) up to day 84

Plasma or urine

baseline (day before Cycle 1 start) up to day 84
CYP/transporter substrate-related adverse events and immune related (ir) adverse events
Tijdsspanne: Baseline (before starting ICI cycle 1) and study visit 2 (up to day 84)

assessed through surveys given to participants

Baseline (before starting ICI cycle 1) and study visit 2 (up to day 84)

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Tyler Shugg, MD, IUSCCC

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 januari 2027

Primaire voltooiing (Geschat)

1 december 2027

Studie voltooiing (Geschat)

1 december 2027

Studieregistratiedata

Eerst ingediend

29 januari 2026

Eerst ingediend dat voldeed aan de QC-criteria

29 januari 2026

Eerst geplaatst (Werkelijk)

5 februari 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

18 november 2026

Laatste update ingediend die voldeed aan QC-criteria

16 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren